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Background: The polysaccharide capsule is a major virulence factor of the important human pathogen
Streptococcus pneumoniae. However, S. pneumoniae strains lacking capsule do occur.
Results: Here, we report a nasopharyngeal isolate of Streptococcus pneumoniae composed of a mixture of two
phenotypes; one encapsulated (serotype 18C) and the other nonencapsulated, determined by serotyping,
electron microscopy and fluorescence isothiocyanate dextran exclusion assay.
By whole genome sequencing, we demonstrated that the phenotypes differ by a single nucleotide base pair in
capsular gene cpsE (C to G change at gene position 1135) predicted to result in amino acid change from arginine
to glycine at position 379, located in the cytoplasmic, enzymatically active, region of this transmembrane protein.
This SNP is responsible for loss of capsule production as the phenotype is transferred with the capsule operon.
The nonencapsulated variant is superior in growth in vitro and is also 117-fold more adherent to and more invasive
into Detroit 562 human epithelial cells than the encapsulated variant.
Expression of six competence pathway genes and one competence-associated gene was 11 to 34-fold higher in
the nonencapsulated variant than the encapsulated and transformation frequency was 3.7-fold greater.
Conclusions: We identified a new single point mutation in capsule gene cpsE of a clinical S. pneumoniae serotype
18C isolate sufficient to cause loss of capsule expression resulting in the co-existence of the encapsulated and
nonencapsulated phenotype. The mutation caused phenotypic changes in growth, adherence to epithelial cells
and transformability. Mutation in capsule gene cpsE may be a way for S. pneumoniae to lose its capsule and
increase its colonization potential.
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The Gram positive bacterium Streptococcus pneumoniae
frequently colonizes the nasopharynx but can also in-
vade the host causing serious illnesses such as pneumo-
nia, meningitis or bacteraemia [1]. A principal virulence
factor of S. pneumoniae is the polysaccharide capsule
protecting it from host immune defences by interfer-
ing with the deposition of complement and therefore* Correspondence: lucy.hathaway@ifik.unibe.ch
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unless otherwise stated.opsonophagocytosis [2-4]. The capsule is the target of all
currently available pneumococcal vaccines including the
13-valent pneumococcal conjugate vaccine (PCV13) for
children. The biochemical structure and linkage of re-
peating polysaccharide subunits determines the serotype
of encapsulated strains. So far, more than 90 different
serotypes have been identified [5-11] which differ in the
type and number of genes encoding the proteins re-
sponsible for transcription, polymerization, elongation
and export of the capsule. For almost all serotypes the
capsule-encoding operon is located between non-capsule
genes dexB and aliA [6,12,13]. The first four genes cpsA,
cpsB, cpsC and cpsD are thought to play a role in regulational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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serotypes [14,15].
Despite the importance of the capsule as a virulence
factor, nonencapsulated pneumococci occur and in the
nasopharynx may represent around 15% of pneumococ-
cal isolates [16]. Nonencapsulated pneumococci are gen-
erally considered not to be virulent but are associated
with outbreaks of conjunctivitis [17-19].
Although lacking the protection from opsonophago-
cytosis which a capsule affords, the absence of capsule
may confer advantages. Nonencapsulated pneumococci
are less sensitive to α-defensins, elastase and cathepsin
G of neutrophils, possibly due to the difference in their
surface charge compared to encapsulated pneumococci
[16,20]. Conversely, capsule might reduce agglutination
by mucus, increasing access to epithelial cells and so
aiding colonization, at least in mice [21] and may con-
tribute to antibiotic tolerance [22].
However, laboratory-generated nonencapsulated mu-
tants have shown that possession of a capsule is a bur-
den for growth [23]. For pneumococci which do have a
capsule, downregulation of its expression in response
to the environment helps colonization by aiding adher-
ence to respiratory epithelial cells [24].
Nonencapsulated S. pneumoniae may be divided into
two groups: those which have aliB-like homologues or
nspA gene in place of capsule genes and those which
have a capsule operon very similar to that of an encap-
sulated strain [25-27]. For the latter, loss of capsule
expression may be due to point mutations in capsule
genes or spontaneous, reversible sequence duplication
or non-reversible deletion within the capsule operon
as described for serotypes 3, 8, 19F and 37 [28-33]. In
the laboratory, nonencapsulated variants can be ob-
tained by knocking out specific genes of the capsule
operon. D39 mutants lacking capsule genes cps2K,
cpsJ or cps2H required suppressor mutations in cpsE
(also denoted as wchA) to survive [34,35]. CpsE is
the initial glycosyltransferase enzyme that catalyzes
the transfer of the activated glucose-phosphate to the
lipid carrier [36-40]. Previous research has shown that a
functional CpsE protein is essential for encapsulation
of pneumococci serotypes 9N, 13, 14, 15B and 19F
[12,37,41].
During our studies of nasopharyngeal clinical isolates
of pneumococci we observed an isolate which gave a
mixture of larger smooth colonies (serotype 18C) and
smaller rough colonies. We aimed to discover whether
this was due to the presence of encapsulated and non-
encapsulated versions of the same strain and, if so, to
uncover the mechanism of the loss of capsule expres-
sion. We compared the two phenotypes in terms of
growth, adherence to epithelial cells and competence
for genetic transformation.Methods
Bacterial strains
Streptococcus pneumoniae strain 307.14 (MLST 113) was
isolated in Switzerland from the nasopharynx of a child
with otitis media and determined to be serotype 18C by
the Quellung reaction as previously described [25,42].
A single colony from the nasopharyngeal swab was
cultured in broth once before freezing the stock. Plating
out of this stock showed that there were two 307.14
variants (encapsulated, nonencapsulated) which were
purified by three consecutive passaging steps where each
time one single colony was picked and streaked on a
Columbia sheep blood agar (CSBA) plate. Separation was
confirmed by serotyping and FITC-dextran exclusion assay
(data not shown).
Serotyping was performed by Quellung reaction with
serotype-specific antisera from the Statens Serum Insti-
tute (Copenhagen, Denmark).
Restriction fragment length polymorphism (RFLP)
analysis was performed as described previously [43],
with the following modifications, to confirm that the
two phenotypes had the same genetic background. The
initial denaturation step was performed for 4 minutes
at 95°C. Denaturation temperature was 95°C in the
30 cycles of PCR. Each reaction was performed in a
total volume of 50 μl with 3 units FastStart Taq DNA
polymerase, 200 μM deoxynucleoside triphosphates,
5 μl 10× PCR reaction buffer (without MgCl2) and
2 mM MgCl2 (all from Roche, Switzerland), 1 μM of
each primer and 100 ng genomic DNA. Endonucleases
AflIII, ApoI, DdeI and MseI (New England Biolabs,
MA, USA) were used for digestion of the PCR product
according the manufacturer’s instructions.
Antibiotic susceptibilities
Etest® strips (AB BIODISK, Solna, Sweden, distributed in
Switzerland by bioMérieux) were used to determine the
minimal inhibitory concentrations (MIC) for the different
antibiotics according to current international recommenda-
tions (www.clsi.org). A sterile cotton swab was soaked in
0.5 McFarland of bacterial culture and then streaked on
agar plates (Mueller Hinton with 5% sheep blood). Ten mi-
nutes later, the Etest® strips were applied on the agar plates
which were then incubated for 24 h and 48 h at 37°C with
5% CO2 atmosphere.
Construction of revertant mutant strains
Capsule switch mutant strains were generated for both
the encapsulated and the nonencapsulated 307.14 wild
type variant using a Janus cassette based on the pub-
lished method [23]. As a first step, a Janus mutant was
made from each of the wild type phenotypes. Next, the
Janus mutant (nonencapsulated) derived from the encap-
sulated wild type was transformed with DNA from the
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307.14 cap-. Also, the Janus mutant derived from the
nonencapsulated wild type was transformed with DNA
from the encapsulated wildtype strain to create the mu-
tant 307.14 cap+. Wild type and mutant strains used in
this study are listed in Table 1 and the amplification and
sequencing primers are listed in Additional file 1: Table
S1. Pneumococcal strain AmiA9 (a kind gift of Regine
Hakenbeck, University of Kaiserslautern, Germany) that
harbours the genotype rpsLK56T conferring streptomycin
resistance [44] served as template for rpsLK56T amplifica-
tion. PCR products were purified using the Wizard® SV
Gel and PCR Clean-Up system (Promega, USA). Stocks
of competent recipient 307.14 variants were prepared by
growing them in brain heart infusion broth (BHI) (Becton
Dickinson, USA) supplemented with 5% fetal bovine serum
(FBS) (Merck, Germany) to mid-logarithmic phase (optical
density (OD600nm) = 0.5–0.8) followed by a 1:20 subculture
in tryptic soy broth (TSB) (Becton Dickinson), pH 7 [45] to
OD600nm = 0.13. Bacteria were harvested by centrifugation
at +4°C and resuspended in TSB, pH 8 + 15% glycerol
(Sigma, USA) for storage at -80°C until use. DNA was
extracted using the QIAamp® DNA Mini Kit (Qiagen,
Germany) following the manufacturer’s instructions. Trans-
formation was based on a previous description [46] diluting
100 μl of thawed competent bacteria in 900 μl fresh TSB
pH 8 supplemented with 200 ng competence stimulating
peptide (CSP-1, PolyPeptide Laboratories, Strasbourg,
France). Bacteria were cultured for 10 min at 37°C
before 500 ng rpsLK56T PCR product, 1 μg dexB-Janus-
aliA PCR product or 2 μg genomic DNA was added and
the samples incubated 20–40 min at 30°C to induce
competence fully, followed by 120 min incubation at
37°C. Serial dilutions made in phosphate-buffered saline
(PBS), pH 7.4 were spread onto CSBA plates containing
300 μg/ml streptomycin and 500 μg/ml kanamycin andTable 1 Wild type and mutant pneumococcal strains used
Strain Serotype Origin/comment
307.14
encapsulated
18C Nasopharyngeal isolate
307.14
nonencapsulated
nonencapsulated Nasopharyngeal isolate
307.14Δcps::
Janus
nonencapsulated Laboratory mutant: strain 307.14
encapsulated which has had its
capsule operon replaced by a
Janus cassette
307.14 cap+ 18C Capsule switch mutant: 307.14
nonencapsulated which has had
its capsule operon replaced by
that of 307.14 encapsulated
307.14 cap- nonencapsulated Capsule switch mutant: 307.14
encapsulated which has had its
capsule operon replaced by that
of 307.14 nonencapsulatedincubated at 37°C with 5% CO2 atmosphere overnight.
Single colonies were subcultured on antibiotic selective
CSBA plates prior to genomic DNA extraction and
strain preservation at -80°C (Technical Service Consultants
Ltd., Heywood, UK). The serotype of the clinical isolates,
the Janus mutants and the capsule switch mutants was
confirmed by the Quellung reaction after transformation.
Insertion of the Janus cassette and replacement and correct
insertion of the donor capsule was confirmed by four con-
trol PCR (see Additional file 1: Table S1) using the iProof
polymerase (Bio-Rad, USA). In order to confirm successful
transfer of cpsE wt and cpsE mutated version, the PCR
product was sequenced by Sanger sequencing. In addition,
PCR and sequencing was also performed at the sites of 6
other SNPs found to differ in the wild type phenotypes to
check that these were not transferred.
Quantification of capsule
Fluorescence isothiocyanate (FITC)-dextran exclusion assay
Capsule thickness was determined using fluorescence
labeled dextran (2 000 kDa, Sigma) based a published
method [47,48]. Bacteria were cultured in 10 ml Lacks
[49-51], 20 mM glucose to OD600nm = 0.5, centrifuged
at 3000 × g for 5 min at room temperature, washed
once with 10 ml of chemically defined medium (CDM) (no
sugars) and then resusupended in 10 ml CDM (no sugars).
800 μl were subcultured in 20 ml CDM, pH 7, 5.5 mM
glucose and grown to OD600nm = 0.25. The bacteria were
harvested by centrifugation and the pellet resuspended in
850 μl pre-chilled phosphate-buffered saline (PBS), pH 7.4.
Bacterial FITC-dextran samples were prepared and visual-
ized using a 100× objective as described [23].
The zone of exclusion of FITC-dextran indicates the
polysaccharide capsule thickness. The experiment was
repeated three times on different days and a total of 15
pictures of the mixed culture (307.14 encapsulated and
307.14 nonencapsulated) were taken. The serotype was
confirmed by Quellung reaction.
Electron microscopy
Bacteria were cultured as described above for the FITC-
dextran exclusion assay, grown to OD600nm of 0.2–0.25
in CDM, pH 7, 5.5 mM glucose and harvested by centri-
fugation. Serotype was confirmed by Quellung reaction
after overnight incubation at 37°C with 5% CO2 atmos-
phere on CSBA plates.
Bacteria were cryopreserved by high-pressure freezing
as described before [52]. Acetone containing 2% os-
mium tetroxide, 0.1% uranyl acetate, 0.2% ruthenium
hexamine trichloride (RHT) and a total of 4% H2O
served as medium for freeze substitution. The RHT
added improves capsule resolution [53]. Electron micro-
graphs from cross-sectional bacterial preparations were
taken at a magnification of 53 000×. The polysaccharide
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bacterial cell wall from at least 30 randomly selected
bacterial cell bodies in 15 pictures using the free soft-
ware ImageJ v1.45 l (National Institutes of Health,
USA, http://imagej.nih.gov/ij). One to four measure-
ments were taken at distinct positions of a given cell
body.Growth assays
Strains were streaked onto CSBA plates and incubated
at 37°C in 5% CO2 overnight and then subcultured in
the semi-defined, nutritionally relatively rich Lacks
medium [49-51] supplemented with 20 mM glucose and
with the following modifications: 14.7 mM C2H3NaO2 ·
3H2O, 5.41 μM CaCl2, 0.89 μM MnSO4 · H2O (all Merck,
Germany) and ≥ 12 800 U catalase (Sigma, C40) per liter
Lacks medium, no NaC2H3O2 and no bovine albumin. For
growth assays, CDM [54] representing a nutritionally lim-
ited environment was used. Since pH may affect growth
and competence, CDM was stabilized using Sørensen buf-
fer (KH2PO4, Na2HPO4 · 2H2O), pH 7 instead of double-
distilled water (Additional file 1: Table S2). Half-loopfuls of
colonies were used to inoculate 10 ml Lacks supplemented
with 20 mM glucose. The bacteria were grown to OD600nm
of 0.5 and frozen at -80°C in aliquots in 15% glycerol.
Thawed bacterial suspensions were diluted in PBS pH 7.4
and plated on CSBA to determine the number of colony
forming units (CFU) per ml the next day. The serotype was
confirmed by Quellung reaction. For growth assays an
inoculum of 5 × 107 CFUs was used for subculture in 20 ml
CDM, 5.5 mM glucose. Bacteria were grown for 10 hours
at 37°C in a water bath and the OD600nm measured
every 30 minutes. Growth assays were repeated on three
different days.Transformation frequency
To compare transformation frequencies between the
two phenotypes the bacteria were cultured as described
for the FITC-dextran exclusion assay and grown to
OD600 = 0.15 in CDM, 5.5 mM glucose, pH 7. 0.5 ml of
the culture were transferred to 9.5 ml TSB competence
medium pH 8.0 prewarmed to 30°C and incubated for
15 min at 30°C. CSP-1 was added to final concentration
of 100 ng/ml and the culture incubated for 15 min at
30°C. 1 μg of chromosomal DNA from streptomycin re-
sistant strain 104.37 (serotype 6B) was added and the
culture incubated for 60 min at 30°C, then for 120 min
at 37°C. Serial dilutions (1:20) in PBS pH 7.4 were plated
onto CSBA plates with and without 300 μg/ml strepto-
mycin. After overnight incubation the number of col-
onies was counted and the transformation frequency
calculated. The serotype was confirmed by Quellung
reaction.Adherence to and invasion of human epithelial cell line
Detroit 562
Detroit nasopharyngeal epithelial cells (ATCC-CCL-138)
were cultured as described [55] in 1× minimum essential
medium (MEM) containing 2 mM L-glutamine, 8.9 mM
sodium bicarbonate, 1 ×MEM non-essential amino acids,
1 mM sodium pyruvate (all Gibco by Life Technologies,
USA), 10% heat-inactivated fetal bovine serum (FBS)
(Merck), 100 U/ml penicillin and 100 μg/ml streptomycin
and grown until reaching complete confluence at 37°C in
5% CO2. For adherence and invasion assays, 500 μl culture
medium (no antibiotics) with 3 × 105 cells was added
per well of a 24-well tissue culture plate and incubated for
24 h. S. pneumoniae was grown as described for the FITC-
dextran exclusion assay in CDM, 5.5 mM glucose, pH 7 to
mid- logarithmic phase (OD600nm = 0.15 for 307.14, encap-
sulated and OD600 = 0.25 for 307.14, nonencapsulated) and
500 μl cell culture medium (no FBS or antibiotics) with
0.9 × 107 bacteria were added to each well containing previ-
ously washed cells (0.85% NaCl). The 24-well plate was
centrifuged at 423 × g for 5 minutes at room temperature.
After incubation for 30 min at 37°C with 5% CO2, the cells
were washed five times with saline to remove non-adherent
bacteria and trypsinized with 200 μl 0.05% trypsin-EDTA
(Gibco by Life Technologies). To determine the number of
invasive bacteria, the gentamicin protection assay described
earlier was followed and the cells co-cultured with bacteria
for 3 h at 37°C with 5% CO2 [55,56]. The cells were washed
five times with saline and 1 ml fresh MEM with gentamicin
sulfate salt (200 μg/ml, Sigma) was added to each well for a
2 h-incubation at 37°C to kill extracellular bacteria. After
washing with saline and trypsinization as described above,
the cells were lysed by addition of 1% saponin (Sigma)
and incubation for 7 minutes at room temperature.
Appropriate dilutions in PBS, pH 7.4 were plated onto
CSBA plates and incubated overnight. The number of
colony-forming units (CFUs) was determined using an
automated colony counter [57]. Adherence and inva-
sion potential of the bacteria was calculated as the
proportion of recovered bacteria to the inoculum. The
serotype was confirmed by Quellung reaction.Whole genome analysis of bacterial genomes
Whole genome sequencing
A barcoded fragment library with 400–500 bp insert size
using “TruSeq DNA TruSeq DNA Sample Preparation Kit”
(Illumina Inc., USA) was prepared for both bacterial ge-
nomes. The samples were sequenced in one lane of an Illu-
mina HiSeq 2000 (Illumina Inc.) together with 23 unrelated
barcoded samples. This resulted in 10,276,620 paired-end
reads (2 × 100 bp) for sample 307.14, encapsulated and
8,715,247 paired-end reads (2 × 100 bp) for sample 307.14,
nonencapsulated.
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The reads of the variants 307.14 nonencapsulated
and 307.14 encapsulated were subjected to de novo
assembly using SPAdes (version 2.4.0, kmer sizes =
33,55,67,81,91,93,95,97,99) [58]. Only scaffolds equal
or longer than 500 bp were used for the further
analyses. The assembly of 307.14 nonencapsulated
resulted in 2088272 bp in 63 scaffolds and a n50
of 79979 bp. The assembly of 307.14 encapsulated
resulted in 2083495 bp in 69 scaffolds and a n50 of
71589 bp.
Polymorphisms detection
To detect assembly errors, for the assemblies of the strains
307.14 nonencapsulated and 307.14 encapsulated a remap-
ping was performed using bowtie2 (version 2.0.0beta6, op-
tions: -N 1 –very-sensitive) [59]. Differences were detected
using samtools (version 0.1.19, mpileup). To detect poly-
morphisms between the two strains, the reads of 307.14
nonencapsulated were mapped to the de novo assembly
307.14 encapsulated and vice versa. The mapping was
performed using bowtie2 (version 2.0.0beta6, options: -N
1 –very-sensitive). Subsequently, polymorphisms of both
mappings were determined using samtools (version 0.1.19,
mpileup) [60].
Gene expression assays
Microarray
Bacteria were cultured as described for the adherence
and invasion assay to mid-logarithmic phase in CDM,
5.5 mM glucose, pH 7. Double volume of RNAprotect®
bacteria reagent (Qiagen, Germany) was added to the
bacterial suspension to stop further transcription. The
samples were vortexed, incubated for 5 min at room
temperature and then centrifuged at 4500 × g for 10 min
at +4°C. The RNA was extracted with the RNeasy® Mini
Kit (Qiagen) following the manufacturer’s instructions
using a Mickle vibratory tissue disintegrator (Mickle
Laboratory Engineering Company Ltd., UK) for mechanical
disruption of the bacteria. Contaminating DNA was re-
moved using the DNA-free™ Kit (Life Technologies) as de-
scribed by the manufacturer. RNA purity, concentration
and quality/integrity were checked using with the Nano-
Drop® spectrophotometer ND-1000 (Thermo Scientific,
USA) and the RNA Nano 6000 kit for the Agilent 2100
bioanalyzer (Agilent Technologies, USA) following the
manufacturer’s instructions. The entire transcriptome
was analyzed by microarray as follows. RNA samples
were hybridised to the BμG@S SPv1.4.0 microarray
designed by the Bacterial Microarray Group at St.
George’s, University of London and manufactured on
the Agilent SurePrint platform (Agilent Technologies).
Labelled cDNA was prepared from 1 μg total RNA
using Cy3-dCTP (GE Healthcare, UK) and SuperScriptII reverse transcriptase with random hexamer primers
(Life Technologies). Labelled cDNA was purified by
Qiagen MinElute column, combined with 10 × CGH
blocking agent and 2 × Hi-RPM hybridisation buffer
(Agilent Technologies) and heated at 95°C for 5 min
prior to loading onto microarray slides which were incu-
bated overnight in an Agilent rotating oven at 65°C,
20 rpm. After hybridization, slides were washed for
5 min at room temperature with CGH Wash Buffer 1
and 1 min at 37°C with CGH Wash buffer 2 (Agilent
Technologies) and scanned immediately, using an
Agilent High Resolution Microarray Scanner, at 5 mi-
cron resolution, 100% PMT. Scanned images were
quantified using Feature Extraction software v 10.7.3.1
(Agilent Technologies) and statistical analysis of raw
intensity data was performed in GeneSpring v12.1
(Agilent Technologies). Data for 3 independent bio-
logical replicate experiments were analysed. Data for
each sample were normalized using a 75th percentile
shift plus baseline normalized to the median of the
related control sample for each biological replicate.
Statistically significant (p < 0.05) differences of more
than 10-fold between the two strains were identified in
an unpaired t-test with Benjamini and Hochberg false
discovery rate correction.Real time RT-PCR
Bacteria were cultured as described for EM in CDM,
5.5 mM glucose, pH 7 to mid-log phase. Double volume
of RNAprotect® bacteria reagent (Qiagen) was added.
RNA was isolated and real-time RT- PCR performed as
described previously to analyze expression of the first
gene of the capsule operon, cpsA and competence gene
comX [61]. The primer sequences for comX were: for-
ward primer, 5′-TGT ATG AAG AAG TCC AAG GGA
CTG T-3′, reverse primer, 5′-GTA AGC AGA GCA
TGC CTT CTT G-3′ and probe 6-FAM-CCC ATA
AAT GAA GGT AAT ATT-MGB_NFQ.Statistical analysis
GraphPad Prism v6.03 software for Windows (www.
graphpad.com) was used to perform the statistical ana-
lysis with the unpaired t test with Welch’s correction.
p ≤ 0.05, two-tailed, was considered significant.Nucleotide sequence accession numbers
The genome raw sequences of the Illumina runs are
deposited in the short reads archive (http://www.ncbi.
nlm.nih.gov/sra): 307.14, encapsulated (SRX485275)
and 307.14, nonencapsulated (SRX485278). BioProject
accession PRJNA241072 (http://www.ncbi.nlm.nih.gov/
bioproject/241072).
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Clinical pneumococcal isolate 307.14 consists of two
variants: one encapsulated and one nonencapsulated
On plating the nasopharyngeal isolate 307.14 onto CSBA
plates, a mixture of large and small colonies was ob-
served. The large colonies made up approximately 50%
of the total and were serotyped as 18C (hereafter re-
ferred to as 307.14 encapsulated) whereas repeated at-
tempts to type the small colonies led to the conclusion
that they were nonencapsulated (hereafter referred to as
307.14 nonencapsulated). RFLP was performed on both
phenotypes and confirmed that they were of the same
genetic background (RFLP type 14, data not shown).
Following subculture in CDM with 5.5 mM glucose, the
bacteria were exposed to FITC-dextran. Figure 1A shows
that by fluorescence microscopy two distinct sizes of
bacteria could be observed. Transmission electron micros-
copy (EM) showed that while the encapsulated bacteriaA
B
D
Figure 1 Nasopharyngeal pneumococcal isolate 307.14 is composed
phenotype is transferred with the capsule operon. Strain 307.14 was cu
microscopy in the presence of FITC-dextran (100× objective). The black arro
the white arrow indicates pneumococci expressing no capsule. The two ph
electron microscopy (EM). (B) 307.14 encapsulated pneumococci expressin
307.14 nonencapsulated pneumococci expressing no visible capsule. Capsu
the two phenotypes were exchanged. (D) “307.14 nonencapsulated” in wh
(creating mutant 307.14 cap+), expressing a thin capsule (marked with a bl
replaced with that of “307.14 nonencapsulated” (creating mutant 307.14 ca
at a magnification of 53 000×.expressed a thick polysaccharide capsule (Figure 1B) the
nonencapsulated expressed no visible capsule (Figure 1C).
To test the stability of the two phenotypes, each puri-
fied wild type variant was streaked onto CSBA plates
and passaged six times over ten days on CSBA plates
followed by culture in Lacks medium with 20 mM glu-
cose on day 4 and day 9 of the experiment. Both pheno-
types were stable as 307.14 encapsulated retained its
capsule as determined by Quellung reaction and FITC-
dextran exclusion assay and 307.14 nonencapsulated also
maintained its phenotype over the repeated passaging
(data not shown).
Loss of capsule expression is due to a single point
mutation in gene cpsE
Polymorphisms for each assembly of the Illumina reads
with a quality score of at least 200× and that were not
detected as assembly error in the remapping were furtherC
E
of encapsulated and nonencapsulated variants and the
ltured in CDM with 5.5 mM glucose and viewed by (A) fluorescence
w indicates pneumococci expressing a large amount of capsule,
enotypes were subcultured separately and viewed by transmission
g a thick polysaccharide capsule (indicated by the black arrow), (C)
le switch mutants were created in which the capsule operons of
ich the operon has been replaced with that of “307.14 encapsulated”
ack arrow). (E) “307.14 encapsulated” in which the operon has been
p-), expressing no detectable capsule. EM pictures (B) to (E) were taken
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307.14 encapsulated and 307.14 nonencapsulated were
revealed (Table 2). One was a switch from cytosine to
guanine at position 1135 of the capsule gene cpsE predicted
to cause a switch from arginine to glycine at position 379 of
the protein.
The role of this SNP in cpsE in loss of capsule expres-
sion was confirmed by exchanging the capsule operons
between the encapsulated and nonencapsulated pheno-
types. When the capsule operon of 307.14 nonencapsu-
lated was replaced by that of 307.14 encapsulated the
expression of an 18C capsule was acquired as determined
by serotyping and electron microscopy (Figure 1D). We
named this mutant 307.14 cap + (Table 1). However, ex-
pression was lower than in the natural encapsulated strain:
The mean thickness of the polysaccharide capsule of 307.14
encapsulated was 137 nm and for 307.14 cap +was 25 nm.
Likewise, replacing the capsule operon of 307.14 en-
capsulated with that of 307.14 nonencapsulated caused
it to lose capsule as shown by electron microscopy
(Figure 1E) and it became nontypeable by Quellung
reaction. We named this mutant 307.14 cap- (Table 1).
The six other SNPs identified by whole genome se-
quencing were not transferred (confirmed by sequen-
cing, see Additional file 1: Table S1) confirming that
the SNP in cpsE is sufficient alone to change the cap-
sule phenotype.
Effect of loss of capsule expression on growth
Comparison of growth in vitro in a chemically defined
medium (CDM) showed that the wild type 307.14Table 2 Single nucleotide polymorphisms (SNPs) upon
change of phenotype from 307.14 encapsulated to
307.14 nonencapsulated
Gene product (TIGR4,
GenBank AE005672.3)
SNP position in
gene (307.14)
Base change
amino acid
change
Undecaprenylphosphate
glucosephosphotransferase
(CpsE) (SP_0350)
1135 C→ G
Arg→ Gly
61 bp upstream ABC transporter,
ATP-binding protein (SP_1282)
not applicable A→ G
not applicable
NOL1/NOP2/sun family
protein (SP_1402)
553 G→ A
Asp→ Asn
Transposase, IS3 family,
degenerate (SP_2018)
not applicable T→ G
not applicable
dlt B protein (SP_2175) 449 A→ G
Stop→ Trp
D-alanine-activating
enzyme (SP_2176)
514 A→ G
Asn→ Asp
Translation elongation
factor Ts (SP_2214)
919 G→ A
Glu→ Lysnonencapsulated, as well as the nonencapsulated labora-
tory mutant 307.14Δcps::Janus, had a clear growth ad-
vantage over 307.14 encapsulated (Figure 2). The lag
phase of growth was shorter and the maximal OD600nm
was higher for both of the nonencapsulated variants
than the encapsulated (replicates shown in Additional
file 1: Figure S1).
Effect of loss of capsule on adherence and invasion
For 307.14 encapsulated 1% of the inoculum adhered
compared to 115% for 307.14 nonencapsulated. The
relative value of adherent nonencapsulated 307.14 bac-
teria was presumably greater than 100% due to growth
of the bacteria during the assay. This represents a 117-
fold greater adherence for the nonencapsulated pheno-
type compared to the encapsulated (Figure 3). Invasion
of the epithelial cells was also greater for the nonencap-
sulated phenotype: 0.22% for 307.14 nonencapsulated
and 0.0012% for 307.14 encapsulated, a difference of
183-fold reflecting the difference in adherence.
Antibiotic susceptibility
There were no significant differences in susceptibility of
the two wild type variants to the antibiotics tested: ampi-
cillin, benzylpenicillin, ceftriaxone, cephalothin, vanco-
mycin, rifampicin, gentamicin, minocycline, tetracycline
and colistin (Additional file 1: Table S3).
Comparison of gene expression between encapsulated
and nonencapsulated variants
Gene expression was investigated by microarray which
showed that 307.14 encapsulated and 307.14 nonencap-
sulated expressed the genes of the capsule operon to an
equal extent. This was confirmed for the first gene of
the capsule operon, cpsA, by real-time RT-PCR (data not
shown). However, seven other genes were upregulated in
307.14 nonencapsulated compared to 307.14 encapsu-
lated between 11 and 34-fold (Table 3). For one of the
genes, comX, expression was also determined by real-
time RT-PCR by three independent experiments, each in
triplicate. Comparing expression to that in the wild type
encapsulated strain, a mean 3 fold higher expression was
found in the wild type nonencapsulated strain, 35 fold
higher in the 307.14 cap- mutant (differing from the wild
type by only the SNP in cpsE) and 52 fold in the Janus
mutant which lacks the entire capsule operon. Using the
student t test with Welch’s correction these differences
are not statistically significant, but the finding that non-
encapsulated variants have a higher expression of comX
than the encapsulated was consistent and in agreement
with the microarray results. Strikingly, all seven genes
identified by microarray were linked to competence,
prompting us to compare the transformation frequencies
between the variants. 307.14 encapsulated showed a mean
Figure 2 Nonencapsulated variant of strain 307.14 has an
advantage over the encapsulated variant in growth. Growth
was measured in vitro in CDM with 5.5 mM glucose by determining
OD600nm over 10 hours. Results show a representative of three
independent experiments (see Additional file 1: Figure S1 for
replicates). Wild type 307.14 encapsulated (●), wild type 307.14
nonencapsulated (■), laboratory mutant 307.14Δcps`:Janus,
nonencapsulated (▲).
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encapsulated of 0.1216% (Figure 4). This represents a
3.7-fold greater transformation frequency by the non-
encapsulated variant compared to the encapsulated
variant (p ≤ 0.05). Expression of no other genes differed
significantly between the encapsulated and nonencap-
sulated phenotypes.Figure 3 Adherence of the two wild type variants to Detroit
562 human epithelial cells. Means from three independent
experiments, each performed in triplicate, are shown. Errors bars
represent SEM. The statistical analysis was performed using
unpaired t test with Welch’s correction.Discussion
Large and small pneumococcal colonies obtained from
the nasopharynx of a child suffering from otitis media
were due to two different patterns of capsule expression
by one strain. The large colonies were due to bacteria
expressing a thick capsule of serotype 18C and the small
colonies were due to bacteria producing no detectable
capsule. The difference was due to a single point muta-
tion in the capsule gene cpsE. The resulting loss of
capsule expression had clear consequences resulting in
increased bacterial growth, adherence to epithelial cells
and competence for genetic transformation. We specu-
late that the mutation occurred in vivo because the
isolate contained an approximately 1:1 ratio of the en-
capsulated and nonencapsulated phenotypes. This is
unlikely to have been achieved during the brief single la-
boratory culture before freezing the sample. We therefore
conclude that the original colony derived directly from the
patient contained a mixture of the encapsulated and nonen-
capsulated phenotypes.
Mutations in cpsE have been shown previously to lead
to loss of capsule expression in clinical isolates. In 2012,
Melchiorre et al., reported two pneumococcal isolates
from patients with bacteraemic pneumonia. These iso-
lates were nonencapsulated but with capsule operons
very similar to those of serotype 7F strains. The isolates
had two distinct point mutations in cpsE both resulting
in premature termination of transcription, CpsE which
was truncated at the C terminus and loss of encapsula-
tion in these two strains [62]. CpsE is the initial glyco-
syltransferase responsible for the addition of activated
glucose-phosphate to the lipid carrier in the bacterial
membrane [36-40]. Laboratory-generated cpsE knock-out
mutants are also nonencapsulated [12]. Here it appears that
an encapsulated and nonencapsulated phenotype can co-
exist in the nasopharynx. It is also the first time a naturally-
occurring mutation in cpsE leading to loss of capsule
expression has been described in a serotype 18C strain.
Unlike the SNP described by Melchiorre et al., the SNP de-
scribed here does not result in a premature stop codon but
rather an amino acid change from arginine to glycine. In
addition, the location of the SNP differs from those de-
scribed previously [34,35,62]. Our data suggest that the
amino acid at position 379 in the cytoplasmic C terminal
region of CpsE is critical for the function of the protein and
therefore polysaccharide capsule production. cpsE is the
first serotype specific gene following the conserved genes
cpsA to cpsD [14,15]. However, there is high sequence
similarity of cpsE gene throughout the serotypes
[12,37-41,63,64] which raises the possibility that SNPs
in cpsE may be a more general phenomenon to control
capsule expression in other serotypes. This mechanism
seems to be irreversible in contrast to the previously
described mechanism of loss of capsule expression by
Table 3 Microarray analysis showing upregulation of
gene expression in 307.14 nonencapsulated versus
307.14 encapsulated phenotype
Gene Function Fold upregulation in
nonencapsulated
comA competence 24
comB competence 27
comD competence 11
comE competence 12
comW competence 22
comX competence 15
orf51 competence-induced bacteriocin B 34
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operon [29,30]. Its irreversible nature, the apparent
complete loss of capsule in the nontypeable phenotype
and the fact that the two phenotypes did not vary in their
expression of virulence gene such as nanA, hylA, pspA and
cbpA differentiate the phenomenon we describe here from
transparent/opaque phase variation [65,66].
We have shown before that loss of capsule affects pheno-
type, especially growth [23] and others have shown that a
loss of capsule is associated with a gain in adherence to epi-
thelial cells [67]. However, in our previous publication we
used laboratory-generated capsule mutants in which the
capsule operon was deleted and replaced by a Janus cas-
sette. Here we show that in a nonencapsulated mutant that
has lost its capsule naturally in vivo we also see the same
effect i.e. an enhancement of growth.
Transformation is an important feature of the pneumo-
coccus and does occur in its natural human environmentFigure 4 Transformation frequencies of the two wild type
variants. Means from three independent experiments are shown.
Error bars represent SEM. The statistical analysis was performed
using unpaired t test with Welch’s correction.[68]. Nonencapsulated strains are known to be more
transformable than encapsulated strains [69] but our
results indicate that this is not only due to a loss of the
barrier of the capsule but also to an upregulation of
genes involved in the competence pathway. Four tem-
porally distinct expression profiles have been described
in competence: early, late and delayed gene induction,
and gene repression [70]. We noted with interest that
the nonencapsulated phenotype had a higher expres-
sion of only the early competence genes compared
to the encapsulated phenotype. Upregulation of early
competence genes has been observed in tissue infec-
tions such as pneumonia and meningitis, but not sep-
sis, and may be linked to the pneumococci being in a
biofilm-like state [71]. Whether the nonencapsulated
phenotype described here is more often associated with
biofilm than the encapsulated phenotype remains to be
investigated.
We did not find a difference in antibiotic susceptibil-
ity between the two phenotypes. Fernebro et al. have
shown that capsule expression reduces antibiotic-
induced lysis however here we measured antibiotic
resistance by Etest® and did not attempt to compare
lytic responses [22].
A limitation of our study is that our isolate was from
one patient at one timepoint. Although the fact that
the two phenotypes were found at a ratio of approxi-
mately 1:1 suggests that they can co-exist in vivo,
we do not know whether over time one phenotype
would out-compete the other. We speculate that the
nonencapsulated variant would have an advantage in
colonization due to better growth and adherence and
also be more able to take up foreign DNA (such as
antibiotic resistance genes) giving it an advantage but
we would need to make a study over time to determine
this.Conclusions
We conclude that cpsE is critical for capsule expression
in multiple serotypes. Mixtures of large and small col-
onies often seen in diagnostic laboratories and inter-
preted to be a mixture of strains could alternatively be
a mixture of an encapsulated strain and its naturally-
occurring nonencapsulated mutant. The link between
loss of capsule expression and increased transformabil-
ity may be due not only to a loss of the capsule barrier
but also due to an upregulation of expression of genes
of the competence pathway.Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
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Additional file 1: Figure S1. Nonencapsulated variant of strain 307.14
has an advantage over the encapsulated variant in growth. This figure
shows two replicates (A and B) of Figure 2. Growth was measured in vitro
in CDM with 5.5 mM glucose by determining OD600nm over 10 hours.
Wild type 307.14 encapsulated (●), wild type 307.14 nonencapsulated (■),
laboratory mutant 307.14Δcps:Janus, nonencapsulated (▲). Table S1:
Amplification and Sequencing Primers. Table S2: Preparation of the
chemically defined medium (CDM). Table S3: Antibiotic susceptibilities.
Minimal inhibitory concentrations (MIC) of the two S. pneumoniae 307.14
wild type variants to selected antibiotics determined by Etest® after 24 h
and 48 h of incubation at 37°C and 5% CO2 atmosphere.
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